Trial · NCT02421172
Adverse events295
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 295
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Ear pain | Ear and labyrinth disorders | Period 1: CJM112 High Dose | 1 | 33 | |
| other | Ear pain | Ear and labyrinth disorders | Period 1: Placebo | 0 | 33 | |
| other | Ear pain | Ear and labyrinth disorders | Extension Period 2: CJM112 High Dose /Placebo | 0 | 29 | |
| other | Ear pain | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 Low Dose | 0 | 16 | |
| other | Ear pain | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 High Dose | 1 | 15 | |
| other | Sudden hearing loss | Ear and labyrinth disorders | Period 1: CJM112 High Dose | 0 | 33 | |
| other | Sudden hearing loss | Ear and labyrinth disorders | Period 1: Placebo | 0 | 33 | |
| other | Sudden hearing loss | Ear and labyrinth disorders | Extension Period 2: CJM112 High Dose /Placebo | 0 | 29 | |
| other | Sudden hearing loss | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 Low Dose | 1 | 16 | |
| other | Sudden hearing loss | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 High Dose | 0 | 15 | |
| other | Tinnitus | Ear and labyrinth disorders | Period 1: CJM112 High Dose | 0 | 33 | |
| other | Tinnitus | Ear and labyrinth disorders | Period 1: Placebo | 0 | 33 | |
| other | Tinnitus | Ear and labyrinth disorders | Extension Period 2: CJM112 High Dose /Placebo | 0 | 29 | |
| other | Tinnitus | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 Low Dose | 1 | 16 | |
| other | Tinnitus | Ear and labyrinth disorders | Extension Period 2: Placebo/CJM112 High Dose | 0 | 15 | |
| other | Eye pruritus | Eye disorders | Period 1: CJM112 High Dose | 0 | 33 | |
| other | Eye pruritus | Eye disorders | Period 1: Placebo | 0 | 33 | |
| other | Eye pruritus | Eye disorders | Extension Period 2: CJM112 High Dose /Placebo | 0 | 29 | |
| other | Eye pruritus | Eye disorders | Extension Period 2: Placebo/CJM112 Low Dose | 1 | 16 | |
| other | Eye pruritus | Eye disorders | Extension Period 2: Placebo/CJM112 High Dose | 0 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02421172/events